Kris Mahadeo

Professor of Pediatrics

Pediatrics, Transplant and Cellular Therapy

kris.mahadeo@duke.edu

Pediatric Transplant and Cellular Therapy, 2400 Pratt Street, Durham, NC 27705

More About This Person

At a Glance

Credentials
1. Education

Academic Experience

Global Scholarship

Keywords

Research

Scholarly Works

Teaching & Mentoring

Recognition

Professional Activities
1. Service to the Profession
2. Leadership & Clinical Positions

Scholarly Works - Conferences

First in vivo hematopoietic stem cell (HSC) gene addition clinical trial: Initial results from EN-374-101 in X-linked chronic granulomatous disease (X-CGD)

Conference MOLECULAR THERAPY · May 8, 2026 Link to item Cite

Primary analysis of the Endrad Trial: Non-Total Body Irradiation (TBI) Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) in Next-Generation-Sequencing Minimal Residual Disease (NGS-MRD) Negative B-Acute Lymphoblastic Leukemia (B-ALL) of Children, Adolescents, and Young Adults (CAYA) with High-Risk/Relapsed B-ALL with Planned Comparisons to the Observational Cohort (Pediatric Transplantation and Cellular Therapy Consortium ONC1701)

Conference TRANSPLANTATION AND CELLULAR THERAPY · February 2026 Link to item Cite

Benign and Malignant Thyroid Nodules after Pediatric HSCT: A 28-Year Single-Center Experience

Conference TRANSPLANTATION AND CELLULAR THERAPY · February 2026 Link to item Cite

Prospective Multi-Center Study of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/ or Multi-Organ Dysfunction Syndrome (POEM Interim Analysis): Baseline Levels of Circulating Angiogenic Factors May Predict Risk of Sinusoidal Obstructive Syndrome.

Conference TRANSPLANTATION AND CELLULAR THERAPY · February 2026 Link to item Cite

Impact of Prior Treatment on the Efficacy of Tabelecleucel for Epstein-Barr Virus-Driven Posttransplant Lymphoproliferative Disease: Subgroup Analysis from the phase 3 Allele Study

Conference TRANSPLANTATION AND CELLULAR THERAPY · February 2026 Link to item Cite

Outcomes Following Graft Failure and Second Subsequent Allogeneic Hematopoietic Cell Transplant in Patients with Sickle Cell Disease: A Multicenter Study

Conference TRANSPLANTATION AND CELLULAR THERAPY · February 2026 Link to item Cite

Improved Hematopoietic Stem Cell Mobilization for Gene Therapy of Hemoglobinopathies Using Single Agent Motixafortide

Conference TRANSPLANTATION AND CELLULAR THERAPY · February 2026 Link to item Cite

ENHANCING PEDIATRIC OUTCOMES IN STEM CELL TRANSPLANTATION: INTEGRATING SCREENING TOOLS FOR COMPREHENSIVE QUALITY OF LIFE ASSESSMENT

Conference BONE MARROW TRANSPLANTATION · November 5, 2025 Link to item Cite

Reduced intensity haploidentical bone marrow transplantation in children with severe sickle cell disease (SCD): BMT CTN 1507

Conference Blood · November 3, 2025 AbstractBackground: Allogeneic hematopoietic stem-cell transplantation has curative potential for sickle cell disease (SCD). Event-free sur ... Full text Cite

Prospective registry of pediatric cellular therapy patients at risk for endothelial dysfunction, sinusoidal obstruction syndrome and/or multi-organ dysfunction syndrome(POEM): pmods as a screening tool for endotheliopathies and critical care admission risk in pediatric HCT patients.

Conference Blood · November 3, 2025 AbstractBackground Pediatric patients undergoing hematopoietic cell transplantation (HCT) may develop life-threatening complications and ne ... Full text Cite

High event-free (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation-sequencing minimal residual disease (NGS-MRD) negative B-acute lymphoblastic leukemia (B-ALL): Results from the EndRAD trial (PTCTC ONC1701)

Conference Blood · November 3, 2025 AbstractIntroduction: HCT is an established curative treatment for children, adolescents, and young adults (CAYA) with high-risk/relapsed B ... Full text Cite

Improved hematopoietic stem cell mobilization for gene therapy using single agent motixafortide in sickle cell disease

Conference Blood · November 3, 2025 AbstractWhile the development and approval of gene therapies (GT) for sickle cell disease (SCD) has transformed treatment options for patie ... Full text Cite

Subgroup analysis based on prior treatment from the Phase 3 allele study of tabelecleucel for epstein-barr virus-driven post-transplant lymphoproliferative disease

Conference Blood · November 3, 2025 AbstractBackground: Tabelecleucel is an off-the-shelf, allogenic Epstein-Barr virus (EBV)-specific cytotoxic T cell therapy for relapsed or ... Full text Cite

Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma

Conference Blood · November 3, 2025 AbstractIntroduction: Brentuximab vedotin (BV) and nivolumab (N) have resulted in significant progress in the treatment of advanced-stage H ... Full text Cite

Updated Clinical Results From the ALLELE Trial: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus (EBV)-Driven Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab Plus Chemotherapy

Conference CLINICAL LYMPHOMA MYELOMA & LEUKEMIA · September 2025 Link to item Cite

Pulmonary Function Outcomes in a Prospective Cohort of Pediatric Allogenic Hematopoietic Cell Transplant Recipients

Conference American Journal of Respiratory and Critical Care Medicine · May 1, 2025 AbstractRATIONALE Pulmonary complications following pediatric allogenic hematopoietic cell transplantation (allo-HCT) are a major cause of morbidity and mortality, but longitudinal lung function data are ... Full text Cite

Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Conference Blood · November 5, 2024 Background: Survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk for treatment-related late effects. Published recommendations for screening/prevention of late com ... Full text Cite

Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Conference Blood · November 5, 2024 Background: Prior studies have reported variable adherence to screening/prevention guidelines from allogeneic hematopoietic cell transplant (HCT) survivors' perspective (Khera N et al. Bi ... Full text Cite

Critical Care Support in Infants Post-Allogeneic HCT: Large Single-Center Cohort Experience

Conference Blood · November 5, 2024 IntroductionAllogeneic hematopoietic cell transplantation (HCT) is a potentially life-saving treatment for various diseases observed in childhood but m ... Full text Cite

Cultured Thymus Tissue Implantation for Congenital Athymia Post FDA Approval: Auto-Immunity and Novel Genetic Mutations

Conference Blood · November 5, 2024 IntroductionCongenital athymiais an ultra-rare cellular immune deficiency characterized by absent T cell thymic emigrants, significant T cell dysfuncti ... Full text Cite

Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy

Conference Blood · November 5, 2024 Background: The ALLELE trial (NCT03394365) is investigating the effects of tabelecleucel, an off-the-shelf allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cell therapy, to treat ... Full text Cite

PRE-HCT NEXT-GENERATION SEQUENCING (NGS-MRD) AND OUTCOMES OF PEDIATRIC, ADOLESCENT, AND YOUNG ADULT B-ALL PATIENTS UNDERGOING ALLOGENEIC HCT: UPDATE FROM THE OBSERVATIONAL ARM OF PTCTC ONC1701

Conference BONE MARROW TRANSPLANTATION · October 2024 Link to item Cite

MDB-83. OUTCOMES OF INFANTS AND YOUNG CHILDREN WITH NEWLY DIAGNOSED SHH MEDULLOBLASTOMA TREATED ON THE NEXT CONSORTIUM “HEAD START” 4 PROTOCOL

Conference Neuro-Oncology · June 18, 2024 AbstractBACKGROUNDInfants and young children with SHH medulloblastoma were demonstrated to have a favorable outcome on “Head Start (HS ... Full text Cite

ATTIL12-T CELL THERAPY FOR SIMULTANEOUSLY DISRUPTING STROMA/TUMORS AND INDUCTION OF ENDOGENOUS TCR-T CELLS

Conference CYTOTHERAPY · June 2024 Link to item Cite

Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507

Conference Blood · November 21, 2023 Background: Allogeneic hematopoietic stem-cell transplantation has curative potential for sickle cell disease (SCD). Event-free survival (EFS) in children with SCD is >90% after a bone marrow transplant (BMT) fro ... Full text Cite

The Impact of Leukapheresis Collection on Patients Undergoing Chimeric Antigen T-Cell Receptor Therapy with Tisagenlecleucel

Conference Blood · November 2, 2023 IntroductionAutologous chimeric antigen receptor T-cell therapy (CAR-T) has revolutionized the treatment of acute lymphoblastic leukemia (ALL) in children and young adolescents, with an ... Full text Cite

A phase 1 dose escalation trial of ex-vivo expanded allogeneic cord blood-derived natural killer cell immunotherapy for pediatric solid tumor malignancies

Conference JOURNAL OF CLINICAL ONCOLOGY · June 1, 2023 Link to item Cite

Tabelecleucel for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease After Failure of Rituximab ± Chemotherapy Following Solid Organ or Allogeneic Hematopoietic Cell Transplant (ALLELE)

Conference AMERICAN JOURNAL OF TRANSPLANTATION · June 2023 Link to item Cite

A phase 1 dose escalation trial of ex-vivo expanded allogeneic cord blood–derived natural killer cell immunotherapy for pediatric solid tumor malignancies.

Conference Journal of Clinical Oncology · June 1, 2023 2546 Background: Despite aggressive multimodality therapy, survival outcomes of most patients with recurrent/refractory solid tumors remain dismal. Preclinical data have shown that natural killer (NK) cells play a significant rol ... Full text Cite

OPTIMIZING VANCOMYCIN DOSING IN THE PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT POPULATION

Conference PEDIATRIC BLOOD & CANCER · June 2020 Link to item Cite

FOOD INSECURITY: THE MD ANDERSON CHILDREN'S CANCER HOSPITAL'S EXPERIENCE WITH A GLOBAL HEALTH CRISIS

Conference PEDIATRIC BLOOD & CANCER · June 2020 Link to item Cite

DNMT3A MUTATIONS IN PEDIATRIC ACUTE MYELOID LEUKEMIA MAY BE ASSOCIATED WITH ADVERSE OUTCOME AND POTENTIALLY IMPACT RISK STRATIFICATION

Conference PEDIATRIC BLOOD & CANCER · June 2020 Link to item Cite

Transfusion Reactions in Pediatric and Young Adult Hematopoietic Stem Cell Transplant and Oncology Patients

Conference BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION · March 2020 Link to item Cite

Immune Effector Cell Associated Neurotoxicity (ICANS) Among Pediatric and AYA Patients: MD Anderson Cancer Center Experience

Conference BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION · March 2020 Link to item Cite

FACTORS ASSOCIATED WITH FAILURE OF NONINVASIVE VENTILATION IN CHILDREN AFTER STEM CELL TRANSPLANT

Conference CRITICAL CARE MEDICINE · January 2020 Link to item Cite

SIMULATION BASED EDUCATION FOR THE EVIDENCE BASED MANAGEMENT OF CHIMERIC ANTIGEN RECEPTOR -T CELL RELATED ENCEPHALOPATHY SYNDROME AND CYTOKINE RELEASE SYNDROME

Conference PEDIATRIC BLOOD & CANCER · June 2019 Link to item Cite

Effects of Vitamin D Levels on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children

Conference BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION · March 2019 Link to item Cite

A Phase 3 Single-Arm, Prospective Study of Remestemcel-L, Ex-Vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Steroid Refractory Acute Gvhd in Pediatric Patients

Conference Biology of Blood and Marrow Transplantation · March 2018 Full text Cite

A Multicenter Review Of High Frequency Oscillatory Ventilation In The Pediatric Hematopoietic Cell Transplant Recipient With Lung Injury

Conference AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE · January 1, 2017 Link to item Cite

The Impact of Neutrophil Engraftment on the Survival of Intubated Pediatric HCT Patients: A Pediatric Acute Lung Injury and Sepsis Network Study

Conference Biology of Blood and Marrow Transplantation · March 2016 Full text Cite

RESPIRATORY PATHOGEN EFFECT ON INTUBATED PEDIATRIC PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANT

Conference CRITICAL CARE MEDICINE · December 1, 2015 Link to item Cite

Durable Engraftment and Correction of Genetic Defect in Children with Congenital Amegakaryocytic Thrombocytopenia Following Myeloablative Umbilical Cord Blood Transplantation

Conference Biology of Blood and Marrow Transplantation · February 2011 Full text Cite

Hydroxyurea Use Among Infants with Sickle Cell Disease: A Survey of Pediatric Hematologists-Oncologists In the United States.

Conference BLOOD · November 19, 2010 Link to item Cite